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Abstract
Recent advances in skin-resident adult stem/progenitor cell research have revealed that these immature and regenerative cells with
a high longevity provide critical functions in maintaining skin homeostasis and repair after severe injuries along the lifespan of indi-
viduals. The establishment of the functional properties of distinct adult stem/progenitor cells found in skin epidermis and hair folli-
cles and extrinsic signals from their niches, which are deregulated during their aging and malignant transformation, has significantly
improved our understanding on the etiopathogenesis of diverse human skin disorders and cancers. Particularly, enhanced ultravio-
let radiation exposure, inflammation and oxidative stress and telomere attrition during chronological aging may induce severe DNA
damages and genomic instability in the skin-resident stem/progenitor cells and their progenies. These molecular events may result
in the alterations in key signalling components controlling their self-renewal and/or regenerative capacities as well as the activation
of tumour suppressor gene products that trigger their growth arrest and senescence or apoptotic death. The progressive decline in
the regenerative functions and/or number of skin-resident adult stem/progenitor cells may cause diverse skin diseases with advanc-
ing age. Moreover, the photoaging, telomerase re-activation and occurrence of different oncogenic events in skin-resident adult
stem/progenitor cells may also culminate in their malignant transformation into cancer stem/progenitor cells and skin cancer initia-
tion and progression. Therefore, the anti-inflammatory and anti-oxidant treatments and stem cell-replacement and gene therapies as
well as the molecular targeting of their malignant counterpart, skin cancer-initiating cells offer great promise to treat diverse skin dis-
orders and cancers.
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Introduction 
Human skin epidermis and its appendages exhibit different site-spe-
cific morphologies and very important physiological functions
including the protection against environmental injury, infection and
excessive dehydration, corporal temperature regulation, and hair
growth maintenance [1–6]. The skin integrity and barrier function
are tightly regulated by a complex network of cell–cell and
cell–matrix interactions. In particular, the cellular regeneration of
skin epidermis and hair follicles is maintained along lifespan of indi-
viduals by different adult stem/progenitor cell subpopulations local-
ized within the specialized microenvironments, niches in basal layer
of epidermis, sebaceous gland and hair follicle bulge region (Fig. 1)
[7–20]. These small subpopulations of immature cells endowed
with a high self-renewal capacity and multilineage differentiation
ability contribute to replenish the different skin cell lineages, includ-
ing mature and specialized keratinocytes, sebocytes or
melanocytes, in homeostatic conditions or after intense skin
injuries. A chronic or cumulative ultraviolet-light (UV) exposure and
inflammation of skin and oxidative stress and telomere shortening
in skin stem/progenitor cells and their progenies, however, usually
lead to their dysfunctions or loss via the senescence or apoptotic
death with advancing age (Figs 1 and 2) [21–28]. This age-related
decline in skin regenerative cells may result in a skin homeostatic
imbalance and severe cutaneous disorders [23–28]. In particular, a
long-term exposure of skin cells to environmental insults such as
UV radiations and internal metabolic reactions typically generates
highly toxic products and reactive free radicals [1, 3, 21, 23, 25–27,
29, 30]. These molecular events may cause severe damages to
mitochondrial and nuclear DNA, membranes, lipids and proteins in
skin-resident stem/progenitor cells and their progenies as well as
dermal fibroblasts, and ultimately lead to cell dysfunctions or loss
during chronological aging. Of therapeutic interest, numerous ther-
apeutic approaches have been developed to restore the skin
integrity and functions with advancing age and improve the repair
mechanisms after severe injuries. The use of antioxidants, anti-
inflammatory and detoxifying agents, calorie restriction and stem
cell-based therapies have emerged as the promising strategies to
prevent or delay the functional decline or loss of skin-resident adult
stem/progenitor cells and their progenies occurring during chrono-
logical aging or photoaging [25, 28, 31–43]. These anti-aging
strategies, which may improve the stress resistance and survival of
skin regenerative cells, represent the potential therapies to prevent
the age-related skin detrimental alterations and disorders such as
premature aging diseases, chronic non-healing wounds and ulcers
and ectodermal dysplasia [25, 28, 31–43].
In addition, the photoaging and accumulation of genetic and/or
epigenetic alterations in skin stem/progenitor cells and their prog-
enies as well as their microenvironment, including age-related
changes in the expression levels of numerous gene products, may
lead to development of cutaneous basal cell and squamous cell
cancers (BCCs and SCCs) or aggressive and recurrent melanoma
(Fig. 1) [1, 4, 6, 13, 22, 28, 44–52]. More specifically, telomere
attrition, the gene mutations leading to inactivation of diverse





toma (pRb) and/or p53] combined with a sustained stimulation of
diverse developmental signalling cascades initiated by distinct
growth factors, and defects in DNA repair mechanisms may con-
tribute to skin cancer initiation and progression (Figs 2 and 3) 
[1, 6, 13, 28, 44–55]. Among the growth factor cascades that are
often deregulated in skin cancer stem/progenitor cells and their
progenies, there are hedgehog, epidermal growth factor receptor
(EGFR), Wingless (Wnt)/b-catenin, Notch, Nodal/Cripto-1, extra-
cellular matrix (ECM)/integrins and/or Polycomb group protein
BIM-1 signalling pathways (Fig. 3). In support with the critical
functions of skin cancer stem/progenitor cells in the skin cancer
development and metastases, small subpopulations of highly
tumorigenic cancer cells with stem cell-like properties have been
identified in situ and isolated from BCCs, SCCs and primary and
secondary melanoma tumours and established skin cancer cell
lines [44, 56–66]. In addition, the development of skin cancers is
generally accompanied by extensive changes in the local microen-
vironment of skin cancer stem/progenitor cells and their progenies
including in their niches and ECM components as well as the secre-
tion of diverse paracrine mitotic factors by activated stromal cells
that contribute to their acquisition of a more malignant behaviour
(Fig. 1) [1, 2, 28, 67–69]. Therefore, the molecular targeting of 
distinct deregulated oncogenic products in skin cancer stem/ 
progenitor cells and their microenvironment offers great promise
to eradicate the total cancer cell mass including skin cancer-
initiating cells and their progenies, and thereby improve the current
cancer therapies.
In this article, we reviewed the specific functions provided by
each adult stem/progenitor cell type in skin maintenance and regen-
eration as well as their potential implications in the development 
of age-related skin disorders and cancers. The emphasis is on the
molecular and cellular mechanisms associated with dysfunctions
or loss of skin-resident adult stem/progenitor cells and their prog-
enies during chronological aging as well as new anti-aging and
cancer therapies to treat a diversity of severe skin disorders and
aggressive cancers.
Functions of skin-resident adult stem/
progenitor cells in skin regeneration
The cellular regeneration of the skin is maintained by different
adult stem/progenitor cell subpopulations localized within the spe-
cialized microenvironments, niches in interfollicular epidermis
(IFE), sebaceous gland and hair follicle bulge region (Fig. 1)
[7–20, 70–72]. The epidermal barrier is affected by a continuous
loss of terminally differentiated keratinocytes in the outermost epi-
dermal layer, the stratum corneum that are shed from the skin sur-
face during the desquamation process [1, 6]. The small clusters of
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undifferentiated and unipotent keratinocyte stem cells (KSCs) with
stem cell-like properties and expressing cytokeratins (CK5/14/15),
p63, a6b4- and a3b1-integrins, and ATP-binding cassette (ABC)
transporters, have been identified near basement membrane in the
basal layer of epithelial compartment (Fig. 1) [2, 7, 8, 10, 11, 13,
70, 73]. KSCs provide critical roles in participating to the continu-
ous replenishment of mature keratinocytes of epidermis in home-
ostatic conditions and after skin injuries [7, 11, 13, 14]. A complex
network of signalling cascades such as EGFR, Notch, insulin-like
growth factor (IGF-1)/IGF-R1, immunoglobulin-like domains 1
(Lrig1), Myc, transforming growth factor-b (TGF-b) and
Polycomb-group protein BMI-1 is involved in the stringent regula-
tion of KSCs behaviour [6, 8–11, 70, 74–79]. The integration of
these diverse signalling pathways in KSCs may result in their pro-
liferation and/or differentiation into keratinocytes during skin tis-
sue regeneration. In this regard, an asymmetric division of KSCs
generates the transit amplifying (TA)/intermediate cells [80]. TA
cells in turn migrate outside the niche and give rise to the interme-
diate keratinocytes and more committed terminally differentiated
keratinocytes constituting various epidermal layers of the skin
[80]. The down-regulation of EGFR in KSCs concomitant with an
enhanced activity of p53 and expression of its targets Notch1 and
p21
WAF1/CIP1
may notably promote the keratinocyte differentiation
[81–83]. Moreover, other signalling effectors, including inhibitor
of kB (IkB) kinase-a (IKK-a), interferon regulatory factor 6 (IRF6)
and cell cycle regulator protein stratifin (SFN, also designated as
14–3-3s protein) also provide critical functions in the regulatory
processes controlling keratinocyte proliferation-differentiation
switch from a mitotic state to a terminally differentiated state [73,
84–89]. Additional studies are however necessary to establish the
precise roles of IRF6, IKK-a and SFN in KSC behaviour versus
their differentiated progenies.
In addition, a small subset of unipotent progenitor cells
expressing CK5/14 and B-lymphocyte-induced maturation protein
Fig. 1 Scheme showing the anatomical localization of skin-resident adult stem/progenitor cell niches and the potential cellular changes associated with
the skin aging and cancers. The small pool of KSCs resident in basal layer of the epithelial compartment are able to regenerate the skin stratified epithe-
lium by replenishing all of the differentiated epithelial keratinocytes, including terminally differentiated keratinocytes at the skin surface lost during desqua-
mation process. Moreover, bESCs in the follicle hair may also replenish the keratinocytes constituting of appendages including sebeceous gland and inter-
follicular epithelium during the hair growth cycle and tissue regeneration after severe skin injury. Additionally, the bulge-resident melanocyte stem cells
may generate the melanocyte precursors that can migrate via ORS to the germinal matrix at the bulg areas of each hair follicle, and thereby replenish the
mature pigmented melanocytes that are responsible for the hair pigmentation by transferring melanin to keratinocytes. This scheme also shows the poten-
tial consequences of the chronological aging of skin stem/progenitor cells including the wrinkles and hair growth defects leading a decreased hair pig-
mentation (greying) and loss. Moreover, the skin cancers including basal cell and squamous cell carcinomas and melanoma which may derive from
genetic alterations in KSCs, bESCs or melanocyte stem cells are indicated. The degradation of collagen in dermal layer through the release of MMPs by
the activated or senescent dermal fibroblasts which may promote the development of skin disorders and invasive cancer subtype is also illustrated.
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1 (BLIMP1) has also been identified near basement membrane
surrounding the cutaneous sebaceous gland in the hair follicle
(Fig. 1) [17]. These skin progenitor cells contribute to regenerate
the sebaceous gland including the terminally differentiated sebo-
cytes that provide important functions in the endocrine and hor-
monal regulation of skin integrity and sebum secretion [5, 17].
Moreover, the multipotent epithelial stem cells (bESCs) expressing
different markers such as CK5/14/15/19, CD200, p63, a6b4- and
a3b1-integrins have been identified in the bulge niche of the hair
follicle (Fig. 1) [8, 9, 12, 15, 16, 22, 71, 90–93]. It has also been
reported that murine bESC may be distinguished from KSCs on
the basis of their CD34 expression while the CD34 marker is not
expressed by human bESCs in bulge niche [12, 71, 94, 95]. A
human CD34
1
subpopulation resident in upper region of the outer
root sheath (ORS) of the hair follicle, however, has been observed
to more effectively regenerate new hair follicle in immunodeficient
nude mouse than CD34
2
cells suggesting that a large niche could
be occupied by human ESCs [96]. bESCs or early progenies serve
as a source of immature cells to regenerate the epidermal cells 
in skin appendages or damaged epithelial tissue in response 
to intense injuries (Fig. 1) [2, 7–9, 12–16, 22, 71, 92–94]. Indeed,
the hair follicles typically undergo repeated growth cycles consisting
Fig. 2 Schematic representation of possible molecular events associated with the dysfunctions or loss of skin-resident stem/progenitor cells. This
scheme suggests that telomere shortening, mutations, DNA repair defects and/or a long-term ultraviolet (UV) exposure of skin-resident stem/progenitor
cells during chronological aging may be accompanied by a decline of their functions or loss. Particularly, the alterations in the growth factor signalling
pathways involved in the stringent control of the self-renewal capacity of these immature cells may lead to their dysfunction. Moreover, the enhanced
expression levels and activation of the p16
INK4A
/retinoblastoma (Rb) and p19
ARF
/p53 cascades may result in an inhibition of CDK/cyclin complexes, inac-
tivation of the E2F transcription factor and growth arrest or senescence. In addition, p53-induced pro-apoptotic factors including Bax, may also trigger
the apoptotic death of these skin regenerative cells with advancing age. In addition, this scheme also specifies that the tumour-suppressing effect medi-
ated through the p16
INK4A
- and/or p53-initaited pathways may counteract the malignant transformation of skin cancer-initiating cells. Alternatively, the
telomerase activation combined with the occurrence of distinct genetic and/or epigenetic alterations leading to inactivation of tumour suppressor genes
and sustained activation of diverse developmental pathways in skin stem/progenitor cells may culminate in their malignant transformation into skin 
cancer stem/progenitor cells and skin tumour formation.
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to the periods of active growth (anagen), regression (catagen) and
rest (telogen). During the hair cycle, the activation of quiescent
bESC subpopulation leads to their division and generation of TA
cells that in turn can leave the bulge niche and migrate along the
ORS forming the outermost layer toward germinal matrix and der-
mal papilla where they can give rise to mature keratinocytes (Fig.
1). In this matter, it has been reported that the induction of telom-
erase or its catalytic subunit, telomerase reverse transcriptase
(TERT) in mouse skin epithelium caused a rapid transition from
the resting phase of hair follicle cycle (telogen) into the active
phase (anagen) by activating hair follicle stem cell proliferation
[97–100]. In fact, TERT may directly promote the entrance of 
quiescent hair follicle stem/progenitor cells into the cell cycle by
modulating the Wnt and Myc pathways [98–101]. The interplay of
a complex network of several developmental signalling cascades
initiated by different growth factors as well as the changes in key
niche components generally participate to the stringent regulation
of bESC behaviour during hair follicle growth and/or IFE regener-
ation after severe injuries [13, 15, 22, 71, 93, 102–106]. These
pathways include sonic hedgehog (SHH/PTCH/GLI), EGFR,
Wnt/b-catenin, Notch, nuclear factor-kappa B (NF-kB), bone mor-
phogenic protein (BMP), BMI-1 and SOX9 transcription factor.
Particularly, the activation of Wnt/b-catenin pathway seems to be
necessary for the fate specification of bESCs into hair follicular
Fig. 3 Scheme showing the potential oncogenic cascades involved in the malignant and aggressive phenotypes of melanoma stem/progenitor cells. The
intracellular signalling cascades induced through the activation of distinct growth factor pathways which may provide a critical role for the sustained
growth, survival, migration, invasion, metastases and/or drug resistance of melanoma stem/progenitor cells, are shown. These tumorigenic cascades
include sonic hedgehog SHH/PTCH (patched receptor)/GLI, Cripto-Nodal-ALK4/7/ActRIIB activin-like kinases receptor complex, CD133 pentaspan
transmembrane protein, Notch/Ligand (Delta and Jagged), hyaluronan (HA)/CD44 and Wnt/Frizzled (Fzd)/b-catenin. The up-regulated expression levels
of certain target gene products including up-regulated cyclin D1, c-Myc, Bcl-2, Nodal, N-cadherin, matrix metalloproteinase (MMPs), urokinase plas-
minogen (uPA), cyclooxygenase (COX-2) and vascular epidermal growth factor (VEGF) that can contribute to the malignant transformation of melanoma
stem/progenitor cells are also indicated. In addition, the potential molecular targeting strategies by using a selective inhibitor of SMO hedgehog sig-
nalling element (cyclopamine), Nodal (Lefty), EGFR (gefitinib or erlotinib), g-secretase and monoclonal antibody (mAb) directed against Cripto-1, CD133
and ABC multidrug transporter.
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keratinocytes rather IFE keratinocytes during hair growth cycle
while Notch signalling may contribute to the maintenance of the
hair follicle fate of bESCs [103, 107–110].
The lower permanent portion of the hair follicle bulge region in
human and mice also contains a small subpopulation of immature
melanocyte stem cells with stem cell-like properties that can give
rise to melanocyte precursors and mature melanocytes in bulb
areas at the base of hair follicle (Fig. 1) [18, 21, 111–115]. The gene
expression analyses of melanocyte stem cells isolated from murine
hair follicles revealed that they express dopachrome tautomerase
(Dct) and paired-box transcription factor PAX3 like melanocytes
[111, 115]. The undifferentiated melanocyte stem cells, however,
may be distinguished from melanocyte precursors and mature
melanocytes by a down-regulated expression of melanocyte-spe-
cific gene products such as microphtalmia-associated transcription
factor (MITF), SRY (sex determining region Y)-box 10, SOX10 tran-
scription factor, lymphoid enhancer-binding factor 1(LEF1), KIT and
tyrosinase-related protein 1 (Tyrp1) [111, 115]. More specifically,
during the anagen phase of hair follicle cycle, activated melanocyte
stem cells in the hair follicle bulge region generate the melanocyte
precursors that migrate along the ORS to regenerate the epidermal
and hair matrix melanocytes (Fig. 1) [18, 21, 112]. The differentiated
and pigmented melanocytes localized at the base of each hair folli-
cle in the bulb areas provide critical functions in hair pigmentation
by producing the specialized melanin-containing vesicles,
melanosomes that are transferred to neighbouring keratinocytes.
Numerous signalling pathways are involved in the stringent regula-
tion of the maintenance of bulge-resident melanocyte stem cells in
quiescent versus activated states as well as in their survival, prolif-
eration, migration and differentiation into melanocyte lineage [18,
21, 113–123]. These signalling elements include Notch1 and 2,
stem cell factor (SCF)/KIT, stromal cell-derived factor-1 (SDF-
1)/CXC chemokine receptor 4 (CXCR4), PAX3, MITF and anti-apop-
totic factor, Bcl-2 [18, 21, 113–123].
In addition, different cell types, which may derive from
pluripotent neural crest stem cells during embryonic develop-
ment, may also be generated from bulge-resident stem cells or
their progenitors in post-natal life in adult mammifers [19, 20,
113, 124–132]. More particularly, the bulge area in human hair
follicle contains a small subpopulation of pluripotent epidermal
neural crest stem cells (eNCSCs) expressing stem cell-like mark-
ers such as nestin, SOX9, Nanog and Oct-3/4 that can give rise to
multiple skin cell lineages including melanocytes, neurons and
smooth muscle cells [20]. Another subpopulation of multipotent
adult skin-derived precursors (SKPs), which reside within the
dermal papillae of hair follicles, also appear to exhibit properties
similar to those of eNCSCs [129, 130, 133]. SKPs can be
expanded in the presence of EGF, basic fibroblast growth factor
(bFGF) and TGF-b and give rise to neurons, glia, smooth muscle
cells, and adipocytes in culture in vitro. Additionally, it has also
been reported that the multipotent human skin-derived CD133
1
cells expressing the CD34 and Thy-1 antigens were able to prolif-
erate in the presence of EGF and bFGF, form spheres, and differ-
entiate into neurons, astrocytes, and rarely into oligodendrocytes
in vitro as well as astrocytes and endothelium in vivo [134].
Future investigations are however necessary to establish the hier-
archical organization of these skin-resident stem/progenitor cells,
and more particularly, to determine whether bulge-resident
melanocyte stem cells or SKPs may arise from more primitive
eNCSCs as well as their specific functions in skin maintenance
and cell regeneration after severe injuries.
On the other hand, the stromal cells including fibroblasts and
dermal sheath cells (DSCs) as well as multipotent dermal-resident
mesenchymal stem cells (MSCs) and endothelial progenitor cells
(EPCs) have been detected in human dermis and vascular well of
skin tissue, respectively [78, 135–137]. Hence, these skin cells
can participate to skin regeneration and cutaneous wound healing
through the release of diverse paracrine factors. More specifically,
the differentiation of EPCs into mature endothelial cells may con-
tribute to the formation of new vessels after severe skin injuries.
Similarly, bone marrow (BM)-derived MSCs and EPCs can also
migrate to severe injured cutaneous tissues such as non-healing
chronic wounds, and thereby take part to skin repair and regener-
ation processes [135, 138, 139].
Collectively, these observations suggest that the interplay of
different types of skin-resident adult stem/progenitor cells 
contribute to the maintenance of skin integrity and functions in
homeostatic conditions and during tissue repair after severe
injuries. Unfortunately, the dysfunctions, loss or malignant
transformation of these rare regenerative skin-resident
stem/progenitor cells during chronological aging or in patho-
logical conditions may result in the development of severe skin
disorders and cancers.
Altered functions of skin-resident 
adult stem/progenitor cells during
chronological aging
The structural integrity and functions of skin are generally
altered with passage of time [1, 3, 21, 25]. The chronological
intrinsic aging of skin cells may result in a progressive
decrease of turnover epidermal time and loss of tone and elas-
ticity of skin [1, 3, 21, 25, 140]. Moreover, the skin aging is
also accompanied by an increased susceptibility to injury and
infection, epidermal dehydratation, reduced wound healing,
wrinkles (rhytides),  pigmentary alterations, hair greying and
loss, blood vessels weakness, and increased risk of skin
epithelial cancers and melanoma (Fig. 1) [1, 3, 21, 25–27,
140]. Among the principal environmental factors that may pro-
mote the skin-aging process and ultimately carcinogenesis, a
repeated exposure to solar UV radiations is  critical [25, 27, 48,
49, 54, 141]. Although the active repair mechanisms and
melanin synthesis may protect the skin cells against UV radia-
tion-induced cellular damages, a chronic or cumulative expo-
sure to sunlight may induce several gene mutations and
 culminate to development of skin disorders such as epidermal
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atrophy, psoriasis, keratosis, depigmentation and dysplasia as
well as skin cancer initiation.
Potential implications of skin-resident stem/
progenitor cells in skin aging-related disorders
Accumulating lines of experimental evidence have revealed that
the chronological or premature aging of skin may be associated
with dysfunctions or loss of certain skin-resident stem/progenitor
cells (Figs 1 and 2) [24, 26–28, 97]. This decline in the functional
properties or number of KSCs and bESCs with the time may impair
the skin regeneration process and wound healing, and contribute
to development of diverse skin disorders [10, 24, 26, 27, 97]. For
instance, the results from a study carried out using the sun-
exposed and sun-protected skin samples obtained from old indi-
viduals revealed that the KSC number was lower in photoaged skin
than in chronologically aged skin specimens [27]. Moreover, it has
been reported that the telomere shortening may occur in hair fol-
licle stem cells with aging, and thereby lead to DNA instability and
a decline in their functional properties including their capacity to
replenish mature and functional keratinocytes and melanocytes of
follicle during the hair growth cycle [97].
The chronological aging and photoaging of skin is also accom-
panied by an extensive ECM remodelling in dermal layers such as
the occurrence of EMT program or senescence of skin fibroblasts,
dramatic up-regulation of matrix metalloproteinases (MMPs) and
a decrease of collagen production (Fig. 1) [140, 142, 143].
Particularly, the fibroblasts in aged skin can produce high levels of
matrix MMPs and low levels of collagen [142]. An exposure of
human skin fibroblasts to UV irradiation may also result in oxida-





-induced fibroblast premature senescence and/or
the activation of the fibroblast to myofibroblast transition [29, 69,
143, 144]. These molecular events may lead to a loss of skin tone
and elasticity, fibrosis and increased risk to develop aggressive
and invasive skin cancers such as melanoma and morphoeic BCC
subtype, which is characterized by an infiltrative growth pattern
and densely fibrous stroma as compared to the most low-risk and
indolent BCCs [29, 68, 69, 144].
In addition, diverse premature aging disorders, which are
typically caused by inherited or sporadic genetic mutations in
key gene products resulting in detrimental nuclear lamina alter-
ations, an accelerated telomere attrition and/or DNA repair
defects, are also associated with an accelerated apparition of
skin aging phenotypes and premature death of patients
[145–152]. The premature aging disorders include Hutchinson-
Gilford progeria syndrome, Werner syndrome, dyskeratosis con-
genital, ataxia-telangiectasia, Fanconi anaemia, aplastic anaemia,
xeroderma pigmentosum (XP), Cockayne syndrome and tri-
chothiodystrophy [145–153]. In general, the genetic abnormali-
ties associated with these diseases may lead to genomic insta-
bility and dysfunctions in adult stem/progenitor cells and their
progenies in diverse tissues including skin. Hence, these accel-
erated aging disorders may be accompanied by a premature loss
of hair and subcutaneous fat, hair greying, severe skin atrophy
and/or an enhanced propensity to develop diverse diseases
including skin disorders and cancers [28, 148–161]. In this
regard, several animal models have been developed to establish
the cellular and molecular events that may promote the aging
process and skin disorder development.
Animal models of skin-resident stem/progenitor
cell aging and disorders
Several studies carried out on mice models have indicated the
potential implication of the senescence or apoptotic death of
skin-resident adult stem/progenitor cells and their progenies in
acquisition of certain premature aging phenotypes and the
pathophysiological development of age-related skin disorders
[21, 97, 116, 119, 152, 162]. For instance, it has been observed
that the telomerase-deficient TERC
–/–
mice with critically short
telomeres, which possess dysfunctional bESCs showing a
reduced ability to be mobilized out of their niche and an impaired
capacity to regenerate the hair follicle and skin epidermis, were
characterized by a premature skin-aging and death [98]. In fact,
bESCs isolated from these telomerase-deficient mice exhibited a
low proliferative capacity ex vivo [98]. Interestingly, the TERT 
re-introduction into late-generation telomerase-deficient TERC
–/–
mice, however, could restore the telomerase activity and 
telomere length and prevent bESC defects and premature skin
pathologies associated with aging and death of mice without
increased the tumorigenesis [98, 163]. In the same pathway, it
has also been reported that the number and proliferative capac-
ity of bESCs were decreased in Zmpste24-null progeroid mice,
which display progeroid symptoms characterized by an aberrant





mutant mice [164]. It has
also been noticed that Wnt and MITF were altered in dysfunc-
tional bESCs and these immature cells and their supporting cells
in the hair bulb region showed an enhanced rate of apoptotic
death [164]. The p53
1/m
or DNp63a mice, which display the
pathological signs associated with premature skin aging-related
phenotypes, were also characterized by a decreased expression
level of nicotinamide adenine dinucleotide (NAD)-dependent
deacytylase protein, sirtuin 1 (SIRT1, silent mating type informa-
tion regulation 2, homologue 1), and reduced longevity relative
to wild-type animal [165]. Importantly, an inhibition or condi-
tional ablation of Notch/Hes1, Bcl-2-dependent SCF/KIT and
master regulator MITF signalling elements also caused a gradual
and dramatic elimination of bulge-resident melanocyte
stem/progenitor cells by apoptosis in animal model in vivo [21,
112, 118–120, 126, 166]. This progressive loss of melanocyte
stem/progenitor cells and their mature progenies, the melanin-
producing melanocytes in the bulb areas, was accompanied by a
severe defect in hair pigmentation and an accelerated and inten-
sive hair greying, the prototypical signs of skin aging (Fig. 1)
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[21, 118–120, 166]. Of particular interest, the hair greying phe-
notype and premature mice death by polycystic kidney disease
observed for Bcl-2
2/2
mice could be prevented by a simultane-
ous down-regulation of pro-apoptotic BH3-only Bcl-2 family
member, BIM suggesting that this factor may constitute a poten-
tial anti-aging therapeutic target [166].
In addition, certain lines of experimental evidence have also
indicated that the activation of p16
INK4A
/pRb and/or p53 tumour
suppressor-induced signalling pathways, which may lead to cellu-
lar senescence or apoptotic death, may contribute to counteract
skin cancer development (Fig. 2) [28, 167–171]. As a matter of
fact, the presence of functional p53 signalling pathway in TERC
2/–
mice, which are deficient in telomerase, has been associated with
an induction of senescence and apoptotic cell death and enhanced





mice, which are able to trigger the senescence
via the p53/ p21CIP1/WAP1 cascade but not apoptosis were resistant
to spontaneous skin tumorigenesis while skin carcinomas were
induced by 7, 12-dimethylbenz[a]anthracene (DMBA) plus 12-O-
tetradecanoylphorbol-13-acetate (TPA) in these mice [171]. In





developed highly proliferative pre-malignant lesions, squamous
papillous/keratoacanthomas and four out of five mice displayed
invasive SCCs despite a high staining of p53/p21
CIP1/WAP1
were
detected in these malignant lesions [171]. In the same way, it
has been observed that the K5TRF2 mice overexpressing telom-
ere-binding factor 2 (TRF2) under control of the regulatory
region of keratin 5 (K5) gene in the stem cell compartment of dif-
ferent epithelia including the skin, exhibited severe premature
skin aging defects with increased age as compared to age-
matched wild-type mice [152, 172]. These skin defects of
K5TRF2 mice include hair loss, skin hyperpigmentation and dry-
ness and an increased predisposition to develop skin cancer
after exposure to light [152, 172]. These skin defects, which
resemble to the skin phenotypes observed in some human pre-
mature aging disorders such as XP syndrome, have been asso-
ciated with a XPF nuclease-dependent telomere loss and
increased chromosomal instability induced through an enhanced
expression of TRF2 and p53 in bESCs leading to their dysfunc-
tion [152]. Importantly, p53 deletion in K5TRF2 mice model
could rescue bESC defects in the absence of telomere elongation
while these K5TRF2/p532/– mice showed an accelerated onset of
pre-neoplastic skin lesions and UV-induced skin carcinogenesis
including BCCs and SCCs relative to K5TRF2, p532/– and/or
wild-type mice used as controls [152].
Altogether, these observations suggest that the induction of
cell cycle arrest and senescence mediated through the stimulation
of tumour suppressor gene products such as p53 may be effective
to decrease the incidence of only certain skin cancer subtypes.
Moreover, the down-regulation of tumour suppressor gene prod-
ucts combined with an accumulation of numerous genetic and/or
epigenetic alterations in skin-resident stem/progenitor cells during
chronological aging or photoaging may also allow them to bypass
the senescence and apoptotic cell death processes and culminate
to skin cancer development.
Altered functions of skin-resident adult
stem/progenitor cells in skin hyperpro-
liferative disorders and cancers








and tensin homologue deleted on chromosome 10 (PTEN),
deregulation of growth factor signalling cascades involved in the
stringent regulation of proliferation, survival and/or differentia-
tion of KSCs and bulge stem cells and photoaging represent
important factors that contribute to development of diverse skin
pathologies (Figs 1 and 2) [6, 51, 55, 83, 173–176]. Among
them, there are the epidermal hyperproliferative disorders such
as impaired wound healing and psoriasis, basaloid follicular
hamartoma and skin cancers including BCCs, SCCs and
melanoma. Particularly, a long-term skin exposure to UV radia-
tions may cause inflammatory and immunosuppressive effects
and DNA damages on sun-exposed areas of skin, and thereby
result in major DNA mutations and photoproduct formation in
skin cells promoting skin cancer initiation [25, 48–50, 52, 162,
177]. For instance, a depletion of cellular antioxidant enzymes
such as catalase and superoxide dismutase (SOD) induced
through an UV light exposure may result in an enhanced reactive
oxygen species (ROS) production and oxidative stress [25, 30].
These molecular events may cause severe damages to DNA, pro-
teins, lipids and carbohydrates in skin cells, and thereby promote
skin cancer development. In this matter, we are reporting fre-
quent deregulation occurring in skin-resident adult
stem/progenitor cells and their progenies which may be associ-
ated with the development of BCCs, SCCs or melanoma.
Potential implications of cancer stem/progenitor
cells in basal cell and squamous cell cancers
Recent studies revealed that an extensive UV light exposure-
induced DNA mutations and genetic and/or epigenetic alterations
leading to a sustained activation of TERT, hedgehog, EGFR
and/or Wnt/b-catenin signalling pathways in skin-resident
stem/progenitor cells and their progenies contribute to the
development of certain cutaneous BCC and SCC subtypes [1, 49,
52, 83, 173, 178]. In this regard, accumulating lines of experi-
mental evidence have indicated that certain subtypes of BCCs
and SCCs could derive from the malignant transformation either
of skin bESCs or their early progenies localized within or in close
proximity to the bulge niche in hair follicles and/or skin cells in
the basal layer of IFE [44, 47, 56, 57, 175, 179, 180]. More par-
ticularly, a sustained activation of sonic hedgehog pathway
SHH/patched (PTCH)/GLI transcription factors, due to an over-
expression of SHH ligand, activating mutations in smoothened
(SMO) co-receptor or inactivating mutations in PTCH receptor as
well as Wnt/b-catenin cascade in skin cells has been associated
with the etiopathogenesis of certain inherited or sporadic BCC
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subtypes in human [49, 102, 180–184]. Consistent with critical
implication of hedgehog cascade in BCCs, it has been shown that
an aberrant expression or activation of hedgehog signalling effec-
tors, including the overexpression of SHH ligand, an activated
human M2SMO mutant or GLI-1 or 2, in skin stem/progenitor
cells found in hair follicles and/or basal layer of epidermis in mice
model in vivo resulted in the cell hyperproliferation and human
BCC-like tumour development [56, 175, 185–192]. Moreover, 
it has been observed that the SOX9 transcription factor, which
represents a potential downstream target of hedgehog pathway 
in hair follicle bESCs, was strongly expressed in cancer cells
detected in BCCs [179]. The ablation of Notch1 receptor in mouse
epidermis by using tissue-specific inducible gene-targeting
approach also resulted in a sustained expression of GLI-2 con-
comitant with the development of epidermal hyperplasia  followed
by BCC-like tumours [193]. These data suggest then that Notch1
may act as a tumour-suppressor gene product in skin epidermis.
In this matter, loss-of-function mutations in PTCH-1 receptor or
activating mutations in SMO resulting in a constitutive activation
of hedgehog pathway, has also been associated with the develop-
ment of rare diseases such as nevoid basal cell carcinoma 
syndrome (NBCCS) and accelerated aging disorder, XP, which 
are typically characterized by skin defects and a high BCC 
incidence [159–161, 183, 186, 194].
On the other hand, an increased expression of CK19, which is
considered as a putative marker of bESCs, has also been
observed in certain SCC tissue specimens [44]. Moreover, a
small subpopulation of murine CD34
1
cancer stem/progenitor
cell population characterized by the phenotypic and functional
properties like normal bESCs has been detected in early stage of
SCCs [57]. The isolated fraction of CD34
1
cancer stem/
progenitor cells were able to give rise to the tumours after trans-
plantation in mice in vivo showing a hierarchical organization
resembling primary malignant neoplasm [57]. The ablation of
the b-catenin gene in these CD34
1
cancer stem/progenitor cells
resulted in their loss and a complete tumour regression suggest-
ing a critical role of the activation of Wnt/b-catenin cascade in
triggering of certain SCC subtypes [57]. The transcriptional
 suppression of p53 induced-Notch gene expression through the
activation of EGFR/c-Jun signalling in keratinocytes also led to a
down-regulation of Notch1-initiated differentiation pathway 
and expansion of stem cell populations that promoted the devel-
opment of SCCs [82, 83]. In spite these advances, additional
investigations are necessary to more precisely determine the
specific implication of KSCs residing near the basement mem-
brane in basal epithelial layer versus bESCs in the development
of different BCC or SCC subtypes (Fig. 1).
Potential implications of cancer stem/progenitor
cells in melanoma
A growing body of experimental evidence has also revealed that
the cutaneous melanoma, which generally shows a high propen-
sity to metastasize and resistance to current therapeutic treat-
ments, could arise from cancer cells endowed with stem cell-like
properties [58–63, 112, 195–198]. In support with this, small
subpopulations of cancer stem/progenitor cells with stem cell-like
properties have been identified and isolated from primary and sec-
ondary tumour specimens of patients with melanoma as well as
human primary WM115 and metastatic WM239A and murine
B16F10 melanoma cell lines [58–63, 65, 195, 196, 198]. These
melanoma stem/progenitor cells expressed different biomarkers
[CD133, CD44, CD20, telomerase reverse transcriptase (TERT),
nestin, Nanog and/or ABC transporters such as MDR-1, ABCG2
and ABCB5]. More specifically, it has been reported that a small
subset of cancer stem/progenitor cells expressing MDR-
1/ABCB2/ABCB5/Nanog/TERT markers, which has been isolated
from primary melanoma specimens, showed higher clonogenicity
and self-renewal capacities in vitro than MDR-1 negative cancer
cell fraction [62]. The ex vivo culture of a CD201 cancer cell frac-
tion enriched from melanoma cell lines and metastases in the
growth medium, which is used for human embryonic stem cells,
also resulted in their propagation under form of non-adherent
spheres [59]. Each individual multipotent CD20
1
cancer cell from
melanoma spheres was able to differentiate like eNCSCs into mul-
tiple cell types showing the phenotypic features like the
melanocytes, adipocytes, osteocytes and chondrocytes under well
definite culture conditions [59]. Moreover, the CD133
1
melanoma
cells isolated from metastatic melanoma biopsies were also able
to form melanocytic tumours in mice in vivo while the CD1332
cancer cell fraction does not induce the melanoma formation [61].
In the same way, a small subpopulation of Cripto-1
1
cells
expressing elevated levels of Oct3/4, Nanog and MDR-1 stem cell-
like markers, which has been isolated from the metastatic
melanoma cell line C8161, also displayed a slow growing and
sphere forming capacity in vitro [199]. Another small side popula-
tion (SP) expressing nestin and premelanosomal marker, gp100
has also been isolated by efflux Hoechst 33342 dye technique
from metastatic melanoma DM1N, DM2N and DM3N cell lines
which were originally established from lymph node melanoma
metastases. It has been observed that these SP cells, which pos-
sessed a small size and were less melanized that other cell frac-
tion, were able to give rise to differentiated melanoma cells. These
SP cells also showed a high resistant to cytosine b-D-arabinofu-
ranoside hydrochloride (Ara-C) treatment [64]. Hence, it appears
that the primary and metastatic melanomas may arise from
tumorigenic cancer cells with the stem cell-like properties.
Particularly, the transition from skin-confined melanoma into inva-
sive and metastatic melanocytic tumours usually implicates an
accumulation of distinct oncogenic events in tumorigenic
melanoma cells.
Molecular events associated with melanoma progression
The progression of primary melanoma into aggressive, invasive
and metastatic melanocytic tumours is usually associated with
a deregulation in numerous signalling elements. Among them,
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there are the alterations in tumour suppressing pathways
including p16
INK4A
/cyclin-dependent kinase 4 (CDK4)/pRb and
p19
ARF
/p53 as well as the activation of multiple growth factor
cascades such as hedgehog, Wnt, Notch, Nodal and diverse
receptor tyrosine kinases (RTKs) such as EGF/EGFR, SCF/KIT
and hepatocyte growth factor/scatter factor (HGF)/c-MET and
activating mutations in KIT (Fig. 3) [46, 53, 66, 174, 200–204].
Particularly, inherited or somatic events including an inactiva-





and PTEN and/or activating mutations in KIT, H-Ras, N-Ras or
B-Raf (v-Raf murine sarcoma viral oncogene homologue B1)
combined with a sustained activation of diverse signalling ele-
ments including Ras/ERK, PI3K/Akt and NF-kB generally con-
tribute to melanoma development (Figs 2 and 3) [55, 177, 201,
205–210]. For instance, the data from an investigation consist-
ing of a 10-year follow-up period of 31 patients with melanoma





and pro-apoptotic factors, Bax and Bak
may be associated with a higher risk of melanoma metastases




protein loss and Ras activation in the development of aggres-






primary melanocytic and multifocal tumours that metastazed to
lymph nodes, lung and liver [66]. The cancer cells expressing
the stem cell-like marker, nestin isolated from primary
melanoma specimen could also be subcutaneously transplanted
in nude mice, and when intravenously injected into non-obese
diabetic-severe combined immunodeficiency (NOD/SCID) mice,
they metastazed at lung [66]. Interestingly, recent data have
also revealed that the stem cell-like markers including CD133,
CD44 and ABCB5 multidrug transporter, which are expressed by
melanoma stem/progenitor cells, can contribute to their malig-
nant behaviour, and thereby they could constitute the potential
molecular therapeutic targets (Fig. 3) [63, 65, 195]. In this mat-
ter, it is worth mentioning that the phenotypic and functional
features of melanoma stem/progenitor cells as well as the num-
ber of melanoma-initiating cells that are able to drive tumour
development may vary during the disease progression and
before and after treatment initiation. As a matter of fact, a high
proportion of human melanoma cells isolated from patients with
primary and metastatic melanomas and expressing different
phenotypic markers were able to form tumours in highly
immunocompromised mice models in vivo [211]. Therefore,
future investigations are required to more precisely definite the
gene expression profiles and functions of specific stem cell-like
markers expressed by melanoma stem/progenitor cells versus
their differentiated progenies in the primary and secondary
melanocytic tumours during cancer etiology and progression.
Particularly, it will be important to establish if melanoma-initiat-
ing cells may derive from the malignant transformation of
bulge-resident stem/progenitor cells like eNCSCs, melanocyte
stem cells and/or their early progenitors endowed with the stem
cell-like properties. These studies should help to develop effec-
tive multitargeted therapies for eradicating the total mass of
melanoma-initiating cells and their progenies at early and late
stages of disease.
Collectively, together these observations suggest a major
implication of dysfunctions or loss of skin-resident adult
stem/progenitor cells in the development of numerous age-related
skin disorders and carcinogenesis. These studies support then the
therapeutic interest to target these immature and dysfunctional
cells to prevent or treat diverse skin disorders and aggressive skin
cancers that may be promoted with the passage of time. In regard
with this, we described new promising anti-aging and cancer ther-
apeutic strategies consisting of stem cell-based therapies and
molecular targeting of deregulated signalling elements in skin can-
cer-initiating cells to treat diverse age-associated skin diseases
and cancers in human.
Novel stem cell-based therapies
Novel anti-aging therapies
Modulation of aging process by calorie 
restriction and pharmacological agents
Numerous studies have revealed that a nutritious diet, also desig-
nated as calorie restriction, use of pharmacological agents includ-
ing anti-inflammatory and antioxidant compounds and activators
of protein deacetylases such as sirtuins (silent information regu-
lators) may represent the potent therapeutic strategies for improv-
ing cell survival and treating diverse metabolic skin disorders [25,
31–34, 212–214]. In fact, calorie restriction or anti-aging skin
cares with these agent types may influence the expression and/or
activity of signalling elements known to be involved in inflamma-
tion, oxidative stress, senescence or apoptotic death of skin-resi-
dent adult stem/progenitor cells and their progenies during
chronological aging [25, 31, 32]. More specifically, the use of acti-
vators of sirtuins, which act as NAD
1
-dependent protein deacety-
lases, may modulate the activity of key gene products including
p53 and forkhead box O (FOXOs) family of transcription factors
that are involved in the regulation of cellular metabolism, stress
resistance, senescence and apoptosis. Thereby, the activators of
sirtuins can promote the cell survival and lifespan extension [31,
32, 215]. For instance, the results from a study consisting in a
topical application on the face and neck of a formulation contain-
ing 1% yeast Kluyveromyces biopeptides acting as a sirtuin 1 acti-
vator carried out with 33 women aged from 37 to 64 years, indi-
cated that this anti-aging skin care significantly improved the
hydration, firmness and pigment colour intensity of skin after 4
weeks of treatment [31]. Moreover, the application of this formu-
lation enriched in yeast Kluyveromyces biopeptides, which
increased the expression levels of nuclear longevity protein sirtuin 1,
also decreased the rate of senescence and apoptotic death
induced by UVB exposure on ex vivo epidermal cell culture
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established from healthy human skin [31]. In the same way, the
use of natural polyphenolic compound, resveratol (trans-3, 49, 
5-trihydroxystilbene) found in red wines and diverse plant species
such as grapes, peanuts, berries and pines, as a skin care ingredi-
ent, has also been shown to induce the anti-inflammatory and
antioxidant effects and enhance the sirtuin enzymatic activity
[33–37, 216, 217]. More specifically, a topical application of
resveratol may reduce cellular ROS levels and prevent the devel-
opment of cutaneous disorders such as skin hyperplasia and can-
cers that may be caused by an UVB light exposure and metabolic
stress during chronological aging [34, 36, 37, 216, 217]. Although
the therapeutic interest to use resveratol in skin care preparations,
it has been reported that this agent, in counterpart, can also poten-
tiate certain types of UVA-induced DNA strand breaks and apop-
totic death of immortalized HaCat human keratinocyte cell line in
vitro [218]. On the other hand, the activation of residual hair
bulge-resident melanocyte stem/progenitor cells and/or their early
progenies also may constitute a potential strategy for recovery
melanin-producing melanocytes in hair bulb areas and treatment
of hypopigmentation disorders such as vitiligo and premature hair
greying [152, 219]. For instance, it has been shown that the topi-
cal application of purified placental sphingolipid induced an
enhanced MITF expression and its target genes via the stimulation
of p38 stress-signalling pathway that restored follicular melanin-
producing melanocytes and hair re-pigmentation in vivo in
C57BL/6J mouse model of age-onset hair greying [152].
Based on these observations, it appears to be important to
more precisely establish the molecular mechanisms associated
with the anti-aging effects induced by calorie restriction, sirtuin
activators and resveratol on skin. Particularly, it will be essential to
estimate their actions on the regenerative capacity and survival of
skin-resident stem/progenitor cells and the maintenance of skin
homeostasis versus their systemic toxicity and tumorigenic poten-
tial at long term. The optimization of the administration mode and
therapeutic doses of these anti-aging agents seems also to be nec-
essary before their use in safe conditions in human beings.
Novel cell-replacement and gene therapies
The in vivo stimulation of endogenous skin-resident adult
stem/progenitor cells or use of ex vivo expanded adult
stem/progenitor cells or their differentiated progenies represent
promising strategies for replacing dysfunctional or lost skin aged
cells or obtaining physiologic tissue-engineered human skin
equivalents for skin grafting after intense injuries [2, 38–43, 78,
135, 220]. Several therapeutic strategies have been investigated
for skin reconstructive surgery after intractable and severe
wounds such as burns, deep skin injuries, infections and decubi-
tus ulcers, including cell grafting with diverse biocompatible arti-
ficial materials and/or skin fragments [39, 40]. For instance, the
use of skin stem/progenitor cells and their progenies engineering
for expressing human TERT or telomere RNA component (TR)
represents a therapy of great interest for treating the chronologi-
cal or premature aging disorders such as Werner progenoid syn-
drome, Fanconi anaemia and chronic dysplastic anaemia which
are associated with the defects in TERT and/or TR leading a
replicative senescence of skin cells [38, 163]. Consistently, it has
been reported that the bulge-resident ESCs in telomerase-deficient
mice showed an impaired proliferative capacity that led to a
decreased skin and hair growth [163]. The telomerase re-intro-
duction in these mice, however, reversed the functional defects
associated with a decreased telomerase activity and telomere
shortening and restored the long-term survival of mice without
increase skin tumorigenesis [163].
In addition, several data have revealed the beneficial effects to
incorporate the dermal cells or BM-derived stem/progenitor cells
for cell-replacement therapy and skin tissue engineering [39, 41,
78, 139]. The incorporation of dermal sheath cells (DSCs) in skin
equivalents that can secrete diverse cytokines including insulin-
growth factor-binding protein-2 (IGFBP-2), has been shown to
enhance the number of putative p63-expressing KSCs, and
improve the epidermal regenerative capacity [78]. Moreover, the
use of cultured autologous BM-derived mesenchymal cells plus
artificial dermis composite graft may also improve mixed
chimerism and vascularized skin graft survival, and thereby pro-
mote the recovery of diverse types of intractable dermatopathies
and prevent graft rejection [39]. Similarly, the inclusion of ex vivo
expanded circulating EPCs from an autologous source onto tis-
sue-engineered human skin substitutes has also been shown to
result in the formation of functional microvessels that improved
the perfusion and survival of bioengineered tissues [40].
Novel cancer therapies targeting skin cancer
stem/progenitor cells and their microenvironment
Since the skin stem/progenitor cells appear to provide critical
functions in BCCs, SCCs and melanoma initiation, invasion and
metastasis at distant sites, treatment resistance and disease
relapse, several anti-cancer strategies have been designed to erad-
icate the total cancer cell mass including skin cancer-initiating
cells and their differentiated progenies. Among the potential
chemopreventive and therapeutic approaches, there are the use of
natural dietary components, specific inhibitors of telomerase,
EGFR, hedgehog, Wnt/b-catenin, Notch, Nodal/Cripto, hyaluronan
(HA)/CD44 and/or SDF-1/CXCR4 signalling cascades and histone
deacetylase (HDAC)-inhibitors as well as the molecular targeting
of anti-apoptotic factors such as Bcl-2 and ABC multidrug trans-
porters (Fig. 3) [1, 83, 192, 202, 221–226]. The results of in vitro
and in vivo studies have revealed a beneficial effect to target these
deregulated signalling elements, alone or in combination thera-
pies, to inhibit the growth, survival, invasion and/or metastasis of
skin cancer cells (Fig. 3) [173, 175, 203, 227–231]. Based on the
observations that the telomerase re-activation may contribute to
cell immortalization and cancer development, including skin can-
cers, several anti-telomerase strategies have been designed to
inhibit the telomerase activity in cancer cells, and prevent the
tumour development [170, 223, 232–236]. Moreover, the natural
dietary component, resveratol has been shown to act as a potent
chemopreventive and chemotherapeutic agent against the 
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chemically- and UVB-induced non-melanoma development by
activating the apoptotic pathways of cell death in mice models of
skin carcinogenesis [35, 36]. Numerous studies have also
revealed the beneficial effects to target the hedgehog signalling
pathway to inhibit the growth and induce the apoptosis of BCC
cells without major toxicity on normal cells [47, 192, 224,
237–239]. Among the hedgehog signalling inhibitor, there are
SMO antagonists including a small molecule CUR61414 and the
plant-derived steroidal alkaloid, cyclopamine or modulators of
sterol levels including 3b-hydroxysteroid (pro-)vitamin D3 and
cholesterol synthesis inhibitors, statins (HMG-CoA reductase
inhibitors) [47, 192, 224, 237–240]. Of particular interest, the data
from a phase 1 clinical trial have also revealed that the treatment
of BCC patients with a hedgehog inhibitor, may reverse the growth
of the tumours in certain patients [241, 242]. Moreover, the inhi-
bition of EGFR and Notch1 signalling using specific EGFR tyrosine
kinase activity inhibitor, AG1478 and g-secretase inhibitor, DAPT
(N-[N-3, 5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl
ester) has also been reported to synergistically induce a substan-
tial rate of apoptotic death of SCC cells [82].
In the case of melanoma, it has been shown that the use of
dominant-negative EGFR, inhibitor of tyrosine kinase activity (TKI)
of EGFR (gefitinib, AG1478 or PD153035) or KIT (imatinib mesy-
late) as well as the blockade of Wnt5/Frizzeld/protein kinase C,
Notch and Nodal/Cripto-1 cascades induced the cytotoxic effect on
melanoma cells [203, 206, 210, 231, 243–246]. The targeting of
HA/CD44 tumorigenic pathway using mAb or soluble CD44 protein
form also diminished the human melanoma growth and/or inci-
dence of metastases in vitro and in mice models in vivo (Fig. 3)
[230, 247–249]. The pharmacologic suppression of MITF tran-
scription factor expression, which provides critical role in the reg-
ulation of differentiation and survival of melanocytic cell lineage
through a topical application of HDAC inhibitor also reduced the
skin pigmentation and melanoma formation in mouse xenografts
derived melanoma cells in vivo [250]. Importantly, the molecular
targeting of sonic hedgehog SHH/PTCH/GLI by using smoothened
co-receptor inhibitor, cyclopamine also prevented the growth,
recurrence, and metastasis of melanoma xenografts in mice in vivo
suggesting that the melanoma-initiating cells may be eliminated
following this treatment type [226]. In this same way, the down-
regulation of CD133 pentaspan transmembrane glycoprotein (pro-
minin-1) in FEMX-I melanoma cells by short hairpin RNAs was also
accompanied by a reduction of cell growth, cell motility, and capac-
ity of cancer cells to form spheroids in vitro [65]. Moreover, the use
of mAb directed against epitope 1 (AC133 and W6B3C1) or epitope
2 (AC141) of the CD133 protein, induced the cytotoxic effects in
FEMX-I cells in vitro and markedly decreased their metastatic
capacity in mice model in vivo (Fig. 3) [65]. The data from microar-
ray analysis have also revealed that several gene products coding
for Wnt inhibitors were up-regulated in the CD133 down-regulated
cells [65]. These observations suggest then that the signalling
pathway initiated through the CD133 stem cell-like marker can also
contribute to malignant phenotype of melanoma stem cells in
cooperation with Wnt cascade, and thereby constitute a potential
molecular therapeutic target to eradicate the melanoma-initiating
cells. Similarly, it has been reported that the use of a mAb directed
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stem cell subpopulation was accompanied by an intracellular dox-
orubicin accumulation that significantly restored drug sensitivity
[58]. Additional characterization of the dose-responses and selec-
tivity of these mAbs on melanoma stem/progenitor cells versus the
normal adult stem cells expressing CD133
1
/ABCB5
1 in vitro and
animal models in vivo is however required before their potential
testing in clinical settings in safe conditions.
Other potential therapeutic strategies against invasive,
metastatic and/or relapsed melanomas also include the
immunotherapy-based melanoma vaccines, chemoimmunothera-
pies with immunosuppressive agents such as interferon-a, gene
therapy and anti-angiogenic therapy by using thalidomine, angio-
statin and/or endostatin, without or plus a stem cell-based trans-
plant [112, 221, 227, 251–255]. More particularly, it has been
reported that the melanoma stem cells, including CD133
1
clono-
genic melanoma cells, express a significant level of cancer testis
antigens (CTAs) suggesting that they could be efficiently targeted
in vivo by CTA-directed immunotherapy [253, 255]. A therapeutic
regimen consisting to 5-fluorocytosine plus engineered neural
stem cells (NSCs) expressing cytosine deaminase, which acts as
a pro-drug activating enzyme, also resulted in a significant reduc-
tion in the tumour border in animal models with established
melanoma brain metastasis in vivo [254].
Conclusions and future directions
Altogether, these recent advancements made in the field of skin-
resident adult stem/progenitor cell biology have provided impor-
tant information on the deregulated signalling cascades that may
contribute to induce their dysfunctions, loss or malignant trans-
formation during the chronological and accelerated aging and
their pathological consequences. Additional studies are however
necessary to more precisely establish the differentially-
expressed gene products in these immature cells versus their
differentiated progenies as well as the changes in their microen-
vironment occurring during human aging process. These future
investigations should shed light onto intrinsic and extrinsic 
factors that may contribute to the progressive decline in regen-
erative capacity or loss of skin-resident adult stem/progenitor
cells, and thereby help to develop new anti-aging strategies for
preventing or delaying the onset of age-related skin disorders in
human beings.
Further identification of specific biomarkers and drug targets 
in skin cancer stem/progenitor cells is also essential to more 
precisely establish their hierarchical organization and phenotypic
features associated with the skin tumour development and pro-
gression from localized cancers in invasive and metastatic stages.
In this regard, the establishment of specific functions of CD133
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